机译:低血清HBsAg和HBV DNA水平识别HBeAg阳性慢性乙型肝炎中埃塞克拉维尔的Pegymated干扰素的最强响应者
Univ Hlth Network Toronto Ctr Liver Dis Toronto ON Canada;
Univ Hlth Network Toronto Ctr Liver Dis Toronto ON Canada;
Jiaotong Univ Ruijin Hosp Dept Infect Dis Shanghai Peoples R China;
Shanghai Publ Hlth Clin Ctr Dept Hepatitis Dis Shanghai Peoples R China;
Erasmus MC Dept Gastroenterol &
Hepatol Rotterdam Netherlands;
Erasmus MC Dept Gastroenterol &
Hepatol Rotterdam Netherlands;
Jiaotong Univ Ruijin Hosp Dept Infect Dis Shanghai Peoples R China;
Shanghai Publ Hlth Clin Ctr Dept Hepatitis Dis Shanghai Peoples R China;
Fudan Univ Zhongshan Hosp Dept Gastroenterol &
Hepatol Shanghai Peoples R China;
Cerrahpasa Med Fac Istanbul Turkey;
Erasmus MC Dept Gastroenterol &
Hepatol Rotterdam Netherlands;
Univ Toronto Toronto Ctr Liver Dis Toronto ON Canada;
机译:O-044:低血清HBsAg和HBV DNA水平识别在HBeAg阳性慢性乙型肝炎中对恩替卡韦的Pegymated干扰素的最强响应者
机译:低乙型肝炎表面抗原和HBV DNA水平预测对乙型肝炎抗原阳性慢性乙型肝炎中的埃内斯切韦的聚乙二醇化干扰素的添加反应
机译:根据正在治疗的HBsAg,HBeAg和HBV DNA水平预测恩替卡韦疗法对HBeAg阳性慢性乙型肝炎患者的反应
机译:慢性乙型肝炎患者IFN-α2b对PBMC HBV-DNA,血清和CD25诱导的负面影响
机译:低乙型肝炎表面抗原和HBV DNA水平可预测乙型肝炎e抗原阳性慢性乙型肝炎对恩替卡韦添加聚乙二醇干扰素的反应
机译:OL-027干扰素治疗的HBsAg阳性慢性乙型肝炎患者血清HBV DNA,HBeAg和HBsAg含量的相关性